Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM1A | O60341 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177339 | 0.92 | ALDH1A1 (0.57) | ALDH1A1KMT2AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL2044509 | 0.85 | ALDH1A1 (0.54) | ALDH1A1KMT2AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL27471526 | 0.85 | ALDH1A1 (0.54) | ALDH1A1KMT2AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL2044506 | 0.85 | ALDH1A1 (0.54) | ALDH1A1KMT2AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL2474471 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KMT2AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL14492202 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KMT2AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL716437 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL19010044 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL1176975 | 0.81 | MAPT (0.56) | ALDH1A1KMT2AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL1506570 | 0.80 | ESR2 (0.58) | ALDH1A1KMT2AMAPK1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713435-B2 | SUCH AS B-PHENYL-GAMMA-BUTYLOLACTONE VIA OXIDATION OF CYCLIC KETONE (3-PHENYLCYCLOBUTANONE) WITH HYDROGEN PEROXIDE/UREA HYDROGEN PEROXIDE IN PRESENCE OF COBALT/SALEN COMPLEX AS CATALYST | KYUSHU UNIVERSITY (JP) | 2004-03-30 | — | — | US | claimed |
| US-20040010152-A1 | Method of producing optically active lactone compound and complex used in the method | KYUSHU UNIVERSITY (JP) | 2004-01-15 | — | — | US | claimed |
| US-20030120091-A1 | Method for producing optically active lactone compounds by using salen cobalt complexes having a cis-beta structure | KYUSHU UNIVERSITY (JP) | 2003-06-26 | — | — | US | claimed |
| EP-1288210-A2 | A method for producing optically active lactone compounds by using salen cobalt complexes having a CIS-Beta structure | KYUSHU UNIVERSITY (JP) | 2003-03-05 | — | — | EP | claimed |
| WO-2025106362-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-116606311-A | Preparation method of compound with methylene cyclobutane structure and preparation method of derivative dimethyl methylene cyclobutane compound | 南开大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-110225911-B | Oxadiazolone transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3544979-B1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| EP-3544979-B1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3544979-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-02 | — | — | EP | disclosed |
| US-6784302-B2 | HIGHER ENANTIOMERIC EXCESS BY USING A SPECIFIED ZIRCONIUM (SALEN) COMPLEX AS CATALYST TO CONDUCT A BAEYER-VILLIGER REACTION OF A CYCLIC KETONE; OXIDATION USING A HYDROGEN PEROXIDE OXIDIZER TO PRODUCE CYCLIC ESTERS | KYUSHU UNIVERSITY (JP) | 2004-08-31 | — | — | US | disclosed |
| US-6713435-B2 | SUCH AS B-PHENYL-GAMMA-BUTYLOLACTONE VIA OXIDATION OF CYCLIC KETONE (3-PHENYLCYCLOBUTANONE) WITH HYDROGEN PEROXIDE/UREA HYDROGEN PEROXIDE IN PRESENCE OF COBALT/SALEN COMPLEX AS CATALYST | KYUSHU UNIVERSITY (JP) | 2004-03-30 | — | — | US | disclosed |
| US-20040010152-A1 | Method of producing optically active lactone compound and complex used in the method | KYUSHU UNIVERSITY (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1352908-A1 | Method of producing optically active lactone compound and complex used in the method | KYUSHU UNIVERSITY (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-20030120091-A1 | Method for producing optically active lactone compounds by using salen cobalt complexes having a cis-beta structure | KYUSHU UNIVERSITY (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1288210-A2 | A method for producing optically active lactone compounds by using salen cobalt complexes having a CIS-Beta structure | KYUSHU UNIVERSITY (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-4035426-A | Diarylcyclobutanes | MEAD JOHNSON & COMPANY (US) | 1977-07-12 | — | — | US | disclosed |
| US-3939196-A | Diarylcyclobutanes | MEAD JOHNSON & COMPANY (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010152-A1 | Method of producing optically active lactone compound and complex used in the method | CYC1, CYP11B1, CYP17A1 | ALDH1A1 338/4885KMT2A 2709/4885MAPK1 1809/4885 |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | ALDH1A1 319/4885KMT2A 4562/4885MAPK1 1446/4885 |
| US-20030120091-A1 | Method for producing optically active lactone compounds by using salen cobalt complexes having a cis-beta structure | SOD1, OAT, SOD3 | ALDH1A1 691/4885KMT2A 2629/4885MAPK1 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.